CASP10 and hematologic disorder: Notably, several drug-gene pairs—including those targeting CASP8, CASP10, KCNQ1, and HSPA8—are not currently approved nor under clinical evaluation for LN, representing investigational candidates with potential for future development in hematologic malignancies.